Global Protease Inhibitors

Protease Inhibitors Comprehensive Study by Application (Commodity Protease Inhibitor, Research Tool Protease Inhibitor, Protease Inhibitor Drugs), Mechanism of Action (Serine Protease Inhibitors, Cysteine Protease Inhibitors, Amino Peptidase Inhibitor, Aspartic Protease Inhibitors, Metalloprotease Inhibitors, Others), End-User (Hospitals & Diagnostic Centers, Pharmaceutical Industries, Academic & Research Institutes), Disease Indication (HIV/AIDS, Hepatitis C, Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema (HAE), Others) Players and Region - Global Market Outlook to 2026

Protease Inhibitors Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Protease inhibitors are a class of antiviral drugs that are generally used to treat hepatitis C and HIV/AIDS. Increasing government initiatives towards research and development in the treatments of the anti-retroviral diseases driving the market growth. For instance, the Food and Drug Administration (FDA), approved HIV‐1 protease inhibitors for the treatment of AIDS/ HIV. In addition, growing research and development activities in the pharmaceutical industry and the growing prevalence of anti-retroviral diseases further propelling market growth.This growth is primarily driven by Growing Prevalence of Anti-Retroviral Diseases and Increasing Number of Patients with Hepatitis C and HIV.

Globally, a noticeable market trend is evident Emphasizing On Development of Pharmaceutical Protease Inhibitor . Major Players, such as Thermo Fisher Scientific Inc. (United States), Sigma-Aldrich, Inc. (United States), CYTOSKELETON, INC. (United States), Merck & Co., Inc. (United States), Genentech, Inc. (Switzerland), Boehringer Ingelheim International GmbH (Germany) and CSL Ltd. (Australia) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Regulatory Insights:
"Based on the U.S. Department of Health and Human Services (HHS) medical practice guidelines following are the drug class approved by the FDA for the treatment of HIV/AIDS. Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors, CCR5 Antagonists, Integrase Inhibitors, Post-Attachment Inhibitors, and Pharmacokinetic Enhancers."

Market Drivers
  • Growing Prevalence of Anti-Retroviral Diseases
  • Increasing Number of Patients with Hepatitis C and HIV

Market Trend
  • Emphasizing On Development of Pharmaceutical Protease Inhibitor
  • Research and Development Activities in the Pharmaceutical Industry

Restraints
  • Stringent Government Regulations Regarding Protease Inhibitors

Opportunities
Growing Awareness about Anti-Retroviral Therapy and Increasing Demand for Protease Inhibitor Drugs
Challenges
Lack of Awareness in the Emerging Economies

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Protease Inhibitors Study Sheds Light on
— The Protease Inhibitors Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Protease Inhibitors industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Protease Inhibitors industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Commodity Protease Inhibitor
  • Research Tool Protease Inhibitor
  • Protease Inhibitor Drugs
By Mechanism of Action
  • Serine Protease Inhibitors
  • Cysteine Protease Inhibitors
  • Amino Peptidase Inhibitor
  • Aspartic Protease Inhibitors
  • Metalloprotease Inhibitors
  • Others

By End-User
  • Hospitals & Diagnostic Centers
  • Pharmaceutical Industries
  • Academic & Research Institutes

By Disease Indication
  • HIV/AIDS
  • Hepatitis C
  • Alpha-1 Antitrypsin Deficiency
  • Hereditary Angioedema (HAE)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Anti-Retroviral Diseases
      • 3.2.2. Increasing Number of Patients with Hepatitis C and HIV
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in the Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Emphasizing On Development of Pharmaceutical Protease Inhibitor
      • 3.4.2. Research and Development Activities in the Pharmaceutical Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Protease Inhibitors, by Application, Mechanism of Action, End-User, Disease Indication and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Protease Inhibitors (Value)
      • 5.2.1. Global Protease Inhibitors by: Application (Value)
        • 5.2.1.1. Commodity Protease Inhibitor
        • 5.2.1.2. Research Tool Protease Inhibitor
        • 5.2.1.3. Protease Inhibitor Drugs
      • 5.2.2. Global Protease Inhibitors by: Mechanism of Action (Value)
        • 5.2.2.1. Serine Protease Inhibitors
        • 5.2.2.2. Cysteine Protease Inhibitors
        • 5.2.2.3. Amino Peptidase Inhibitor
        • 5.2.2.4. Aspartic Protease Inhibitors
        • 5.2.2.5. Metalloprotease Inhibitors
        • 5.2.2.6. Others
      • 5.2.3. Global Protease Inhibitors by: End-User (Value)
        • 5.2.3.1. Hospitals & Diagnostic Centers
        • 5.2.3.2. Pharmaceutical Industries
        • 5.2.3.3. Academic & Research Institutes
      • 5.2.4. Global Protease Inhibitors by: Disease Indication (Value)
        • 5.2.4.1. HIV/AIDS
        • 5.2.4.2. Hepatitis C
        • 5.2.4.3. Alpha-1 Antitrypsin Deficiency
        • 5.2.4.4. Hereditary Angioedema (HAE)
        • 5.2.4.5. Others
      • 5.2.5. Global Protease Inhibitors Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Protease Inhibitors (Price)
  • 6. Protease Inhibitors: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sigma-Aldrich, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CYTOSKELETON, INC. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genentech, Inc. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boehringer Ingelheim International GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CSL Ltd. (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Protease Inhibitors Sale, by Application, Mechanism of Action, End-User, Disease Indication and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Protease Inhibitors (Value)
      • 7.2.1. Global Protease Inhibitors by: Application (Value)
        • 7.2.1.1. Commodity Protease Inhibitor
        • 7.2.1.2. Research Tool Protease Inhibitor
        • 7.2.1.3. Protease Inhibitor Drugs
      • 7.2.2. Global Protease Inhibitors by: Mechanism of Action (Value)
        • 7.2.2.1. Serine Protease Inhibitors
        • 7.2.2.2. Cysteine Protease Inhibitors
        • 7.2.2.3. Amino Peptidase Inhibitor
        • 7.2.2.4. Aspartic Protease Inhibitors
        • 7.2.2.5. Metalloprotease Inhibitors
        • 7.2.2.6. Others
      • 7.2.3. Global Protease Inhibitors by: End-User (Value)
        • 7.2.3.1. Hospitals & Diagnostic Centers
        • 7.2.3.2. Pharmaceutical Industries
        • 7.2.3.3. Academic & Research Institutes
      • 7.2.4. Global Protease Inhibitors by: Disease Indication (Value)
        • 7.2.4.1. HIV/AIDS
        • 7.2.4.2. Hepatitis C
        • 7.2.4.3. Alpha-1 Antitrypsin Deficiency
        • 7.2.4.4. Hereditary Angioedema (HAE)
        • 7.2.4.5. Others
      • 7.2.5. Global Protease Inhibitors Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Protease Inhibitors (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Protease Inhibitors: by Application(USD Million)
  • Table 2. Protease Inhibitors Commodity Protease Inhibitor , by Region USD Million (2015-2020)
  • Table 3. Protease Inhibitors Research Tool Protease Inhibitor , by Region USD Million (2015-2020)
  • Table 4. Protease Inhibitors Protease Inhibitor Drugs , by Region USD Million (2015-2020)
  • Table 5. Protease Inhibitors: by Mechanism of Action(USD Million)
  • Table 6. Protease Inhibitors Serine Protease Inhibitors , by Region USD Million (2015-2020)
  • Table 7. Protease Inhibitors Cysteine Protease Inhibitors , by Region USD Million (2015-2020)
  • Table 8. Protease Inhibitors Amino Peptidase Inhibitor , by Region USD Million (2015-2020)
  • Table 9. Protease Inhibitors Aspartic Protease Inhibitors , by Region USD Million (2015-2020)
  • Table 10. Protease Inhibitors Metalloprotease Inhibitors , by Region USD Million (2015-2020)
  • Table 11. Protease Inhibitors Others , by Region USD Million (2015-2020)
  • Table 12. Protease Inhibitors: by End-User(USD Million)
  • Table 13. Protease Inhibitors Hospitals & Diagnostic Centers , by Region USD Million (2015-2020)
  • Table 14. Protease Inhibitors Pharmaceutical Industries , by Region USD Million (2015-2020)
  • Table 15. Protease Inhibitors Academic & Research Institutes , by Region USD Million (2015-2020)
  • Table 16. Protease Inhibitors: by Disease Indication(USD Million)
  • Table 17. Protease Inhibitors HIV/AIDS , by Region USD Million (2015-2020)
  • Table 18. Protease Inhibitors Hepatitis C , by Region USD Million (2015-2020)
  • Table 19. Protease Inhibitors Alpha-1 Antitrypsin Deficiency , by Region USD Million (2015-2020)
  • Table 20. Protease Inhibitors Hereditary Angioedema (HAE) , by Region USD Million (2015-2020)
  • Table 21. Protease Inhibitors Others , by Region USD Million (2015-2020)
  • Table 22. South America Protease Inhibitors, by Country USD Million (2015-2020)
  • Table 23. South America Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 24. South America Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 25. South America Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 26. South America Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 27. Brazil Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 28. Brazil Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 29. Brazil Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 30. Brazil Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 31. Argentina Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 32. Argentina Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 33. Argentina Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 34. Argentina Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 35. Rest of South America Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 36. Rest of South America Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 37. Rest of South America Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 38. Rest of South America Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 39. Asia Pacific Protease Inhibitors, by Country USD Million (2015-2020)
  • Table 40. Asia Pacific Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 41. Asia Pacific Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 42. Asia Pacific Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 43. Asia Pacific Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 44. China Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 45. China Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 46. China Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 47. China Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 48. Japan Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 49. Japan Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 50. Japan Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 51. Japan Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 52. India Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 53. India Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 54. India Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 55. India Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 56. South Korea Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 57. South Korea Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 58. South Korea Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 59. South Korea Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 60. Taiwan Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 61. Taiwan Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 62. Taiwan Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 63. Taiwan Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 64. Australia Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 65. Australia Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 66. Australia Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 67. Australia Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 72. Europe Protease Inhibitors, by Country USD Million (2015-2020)
  • Table 73. Europe Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 74. Europe Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 75. Europe Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 76. Europe Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 77. Germany Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 78. Germany Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 79. Germany Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 80. Germany Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 81. France Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 82. France Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 83. France Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 84. France Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 85. Italy Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 86. Italy Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 87. Italy Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 88. Italy Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 89. United Kingdom Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 90. United Kingdom Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 91. United Kingdom Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 92. United Kingdom Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 93. Netherlands Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 94. Netherlands Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 95. Netherlands Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 96. Netherlands Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 97. Rest of Europe Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 98. Rest of Europe Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 99. Rest of Europe Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 100. Rest of Europe Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 101. MEA Protease Inhibitors, by Country USD Million (2015-2020)
  • Table 102. MEA Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 103. MEA Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 104. MEA Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 105. MEA Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 106. Middle East Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 107. Middle East Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 108. Middle East Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 109. Middle East Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 110. Africa Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 111. Africa Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 112. Africa Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 113. Africa Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 114. North America Protease Inhibitors, by Country USD Million (2015-2020)
  • Table 115. North America Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 116. North America Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 117. North America Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 118. North America Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 119. United States Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 120. United States Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 121. United States Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 122. United States Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 123. Canada Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 124. Canada Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 125. Canada Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 126. Canada Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 127. Mexico Protease Inhibitors, by Application USD Million (2015-2020)
  • Table 128. Mexico Protease Inhibitors, by Mechanism of Action USD Million (2015-2020)
  • Table 129. Mexico Protease Inhibitors, by End-User USD Million (2015-2020)
  • Table 130. Mexico Protease Inhibitors, by Disease Indication USD Million (2015-2020)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Protease Inhibitors: by Application(USD Million)
  • Table 139. Protease Inhibitors Commodity Protease Inhibitor , by Region USD Million (2021-2026)
  • Table 140. Protease Inhibitors Research Tool Protease Inhibitor , by Region USD Million (2021-2026)
  • Table 141. Protease Inhibitors Protease Inhibitor Drugs , by Region USD Million (2021-2026)
  • Table 142. Protease Inhibitors: by Mechanism of Action(USD Million)
  • Table 143. Protease Inhibitors Serine Protease Inhibitors , by Region USD Million (2021-2026)
  • Table 144. Protease Inhibitors Cysteine Protease Inhibitors , by Region USD Million (2021-2026)
  • Table 145. Protease Inhibitors Amino Peptidase Inhibitor , by Region USD Million (2021-2026)
  • Table 146. Protease Inhibitors Aspartic Protease Inhibitors , by Region USD Million (2021-2026)
  • Table 147. Protease Inhibitors Metalloprotease Inhibitors , by Region USD Million (2021-2026)
  • Table 148. Protease Inhibitors Others , by Region USD Million (2021-2026)
  • Table 149. Protease Inhibitors: by End-User(USD Million)
  • Table 150. Protease Inhibitors Hospitals & Diagnostic Centers , by Region USD Million (2021-2026)
  • Table 151. Protease Inhibitors Pharmaceutical Industries , by Region USD Million (2021-2026)
  • Table 152. Protease Inhibitors Academic & Research Institutes , by Region USD Million (2021-2026)
  • Table 153. Protease Inhibitors: by Disease Indication(USD Million)
  • Table 154. Protease Inhibitors HIV/AIDS , by Region USD Million (2021-2026)
  • Table 155. Protease Inhibitors Hepatitis C , by Region USD Million (2021-2026)
  • Table 156. Protease Inhibitors Alpha-1 Antitrypsin Deficiency , by Region USD Million (2021-2026)
  • Table 157. Protease Inhibitors Hereditary Angioedema (HAE) , by Region USD Million (2021-2026)
  • Table 158. Protease Inhibitors Others , by Region USD Million (2021-2026)
  • Table 159. South America Protease Inhibitors, by Country USD Million (2021-2026)
  • Table 160. South America Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 161. South America Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 162. South America Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 163. South America Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 164. Brazil Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 165. Brazil Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 166. Brazil Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 167. Brazil Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 168. Argentina Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 169. Argentina Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 170. Argentina Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 171. Argentina Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 172. Rest of South America Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 173. Rest of South America Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 174. Rest of South America Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 175. Rest of South America Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 176. Asia Pacific Protease Inhibitors, by Country USD Million (2021-2026)
  • Table 177. Asia Pacific Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 178. Asia Pacific Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 179. Asia Pacific Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 180. Asia Pacific Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 181. China Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 182. China Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 183. China Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 184. China Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 185. Japan Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 186. Japan Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 187. Japan Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 188. Japan Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 189. India Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 190. India Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 191. India Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 192. India Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 193. South Korea Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 194. South Korea Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 195. South Korea Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 196. South Korea Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 197. Taiwan Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 198. Taiwan Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 199. Taiwan Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 200. Taiwan Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 201. Australia Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 202. Australia Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 203. Australia Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 204. Australia Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 209. Europe Protease Inhibitors, by Country USD Million (2021-2026)
  • Table 210. Europe Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 211. Europe Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 212. Europe Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 213. Europe Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 214. Germany Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 215. Germany Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 216. Germany Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 217. Germany Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 218. France Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 219. France Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 220. France Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 221. France Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 222. Italy Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 223. Italy Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 224. Italy Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 225. Italy Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 226. United Kingdom Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 227. United Kingdom Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 228. United Kingdom Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 229. United Kingdom Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 230. Netherlands Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 231. Netherlands Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 232. Netherlands Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 233. Netherlands Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 234. Rest of Europe Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 235. Rest of Europe Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 236. Rest of Europe Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 237. Rest of Europe Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 238. MEA Protease Inhibitors, by Country USD Million (2021-2026)
  • Table 239. MEA Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 240. MEA Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 241. MEA Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 242. MEA Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 243. Middle East Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 244. Middle East Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 245. Middle East Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 246. Middle East Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 247. Africa Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 248. Africa Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 249. Africa Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 250. Africa Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 251. North America Protease Inhibitors, by Country USD Million (2021-2026)
  • Table 252. North America Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 253. North America Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 254. North America Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 255. North America Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 256. United States Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 257. United States Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 258. United States Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 259. United States Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 260. Canada Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 261. Canada Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 262. Canada Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 263. Canada Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 264. Mexico Protease Inhibitors, by Application USD Million (2021-2026)
  • Table 265. Mexico Protease Inhibitors, by Mechanism of Action USD Million (2021-2026)
  • Table 266. Mexico Protease Inhibitors, by End-User USD Million (2021-2026)
  • Table 267. Mexico Protease Inhibitors, by Disease Indication USD Million (2021-2026)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Protease Inhibitors: by Application USD Million (2015-2020)
  • Figure 5. Global Protease Inhibitors: by Mechanism of Action USD Million (2015-2020)
  • Figure 6. Global Protease Inhibitors: by End-User USD Million (2015-2020)
  • Figure 7. Global Protease Inhibitors: by Disease Indication USD Million (2015-2020)
  • Figure 8. South America Protease Inhibitors Share (%), by Country
  • Figure 9. Asia Pacific Protease Inhibitors Share (%), by Country
  • Figure 10. Europe Protease Inhibitors Share (%), by Country
  • Figure 11. MEA Protease Inhibitors Share (%), by Country
  • Figure 12. North America Protease Inhibitors Share (%), by Country
  • Figure 13. Global Protease Inhibitors share by Players 2020 (%)
  • Figure 14. Global Protease Inhibitors share by Players (Top 3) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Sigma-Aldrich, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Sigma-Aldrich, Inc. (United States) Revenue: by Geography 2020
  • Figure 20. CYTOSKELETON, INC. (United States) Revenue, Net Income and Gross profit
  • Figure 21. CYTOSKELETON, INC. (United States) Revenue: by Geography 2020
  • Figure 22. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Genentech, Inc. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Genentech, Inc. (Switzerland) Revenue: by Geography 2020
  • Figure 26. Boehringer Ingelheim International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Boehringer Ingelheim International GmbH (Germany) Revenue: by Geography 2020
  • Figure 28. CSL Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 29. CSL Ltd. (Australia) Revenue: by Geography 2020
  • Figure 30. Global Protease Inhibitors: by Application USD Million (2021-2026)
  • Figure 31. Global Protease Inhibitors: by Mechanism of Action USD Million (2021-2026)
  • Figure 32. Global Protease Inhibitors: by End-User USD Million (2021-2026)
  • Figure 33. Global Protease Inhibitors: by Disease Indication USD Million (2021-2026)
  • Figure 34. South America Protease Inhibitors Share (%), by Country
  • Figure 35. Asia Pacific Protease Inhibitors Share (%), by Country
  • Figure 36. Europe Protease Inhibitors Share (%), by Country
  • Figure 37. MEA Protease Inhibitors Share (%), by Country
  • Figure 38. North America Protease Inhibitors Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific Inc. (United States)
  • Sigma-Aldrich, Inc. (United States)
  • CYTOSKELETON, INC. (United States)
  • Merck & Co., Inc. (United States)
  • Genentech, Inc. (Switzerland)
  • Boehringer Ingelheim International GmbH (Germany)
  • CSL Ltd. (Australia)
Additional players considered in the study are as follows:
Grifols S.A (Spain) , Takeda Pharmaceuticals (Japan)
Select User Access Type

Key Highlights of Report


Mar 2022 245 Pages 81 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Protease Inhibitors Quantitative research analysis
Global Protease Inhibitors Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Protease Inhibitors Market are Thermo Fisher Scientific Inc. (United States), Sigma-Aldrich, Inc. (United States), CYTOSKELETON, INC. (United States), Merck & Co., Inc. (United States), Genentech, Inc. (Switzerland), Boehringer Ingelheim International GmbH (Germany) and CSL Ltd. (Australia) etc.
Protease inhibitors are a class of antiviral drugs that are generally used to treat hepatitis C and HIV/AIDS. Increasing government initiatives towards research and development in the treatments of the anti-retroviral diseases driving the market growth. For instance, the Food and Drug Administration (FDA), approved HIV&

Know More About Global Protease Inhibitors Report?

Have a Query? Click Here

Other Related Reports

Diabetic Gastroparesis Treatment Comprehensive Study by Type (Drugs, Surgical Treatment Products), Application (Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce), By T...
$ 3750
Antibacterial Washcloth Comprehensive Study by Type (Mix type, Cotton, Bamboo Extract, Linen, Other Materials), Application (Patient and peri-care, Bathing, General Cleaning, Housekeeping) Players an...
$ 3500
Hypereosinophilic Syndrome Drug Comprehensive Study by Type (Benralizumab, Dasatinib, Dexpramipexole Dihydrochloride, Mepolizumab, Others), Application (Research Center, Hospital, Clinic) Players and...
$ 3500
Pulmonary Hypertension Drug Comprehensive Study by Type (IK-3001, Sildenafil Citrate IMD, IK-7002, Riociguat, SAR-407899, Others), Application (Early-Stage Drug Candidates (Phase I & Phase II), Late-...
$ 3450
Pharmaceutical Filtration Comprehensive Study by Type (Membrane Filters {MCE Membrane Filters, Coated Cellulose Acetate Membrane Filters, Nylon Membrane Filters, PTFE Membrane Filters, PVDF Membrane...
$ 3750
Hemophilia Drugs Comprehensive Study by Type (Hemlibra, Benefix, Advate, Novoseven RT, Eloctate, Humate-P, Others), Application (Recombinant Therapies, Plasma-Derived Therapies), Distribution Channel...
$ 3750